Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 180 participants.
Also called NCT05331144
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 180 participants
- Registry
-
NCT05331144
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05331144. Randomized; single masking; primary purpose prevention. Start 2022-10-25 (actual); primary completion 2028-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
- Acronym
- IPAT
- Condition
- Cognitively Normal Older Adults
- Condition
- Hypertension
- Condition
- Subjective Cognitive Decline
- Condition
- Family History of Dementia
- Intervention (Drug)
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
- Intervention (Other)
- PCP
- Lead sponsor
- Rong Zhang
- Collaborator
- National Institute on Aging (NIA)
- Collaborator
- Texas Health Resources
- Collaborator
- Michigan State University
Record details
- Record id
cardio:ct-nct05331144- Content hash
91ebd4c5120ac94ff77612efbb3a228f0617356f572f7a840f8353fa7fb23b1d